Final answer:
Dupixent (dupilumab) is a treatment for atopic dermatitis (eczema), asthma, and nasal polyposis, functioning as a monoclonal antibody to reduce inflammation by targeting specific interleukins.
Step-by-step explanation:
Dupixent (dupilumab) is currently one of the latest treatments for moderate to severe atopic dermatitis (eczema), and it has also been approved for use in treating other conditions such as asthma and chronic rhinosinusitis with nasal polyposis. Dupilumab is a monoclonal antibody that works by blocking interleukin-4 and interleukin-13, which are part of the immune response that contributes to inflammation in these diseases. The administration of Dupixent is through subcutaneous injection. Being one of the newer treatments on the market, it has provided an additional option for patients who may not have responded well to traditional therapies.